Healthcare Services

Key Insights On The Endometriosis Market 2024 – Size, Driver, And Major Players

December 22, 2023 by The Business Research Company

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

As per The Business Research Company’s Endometriosis Global Market Report 2023, the endometriosis market is expected to show significant growth in the forecast period.

The endometriosis market has witnessed a remarkable surge in recent years, evolving from a $1.27 billion industry in 2023 to an anticipated $1.4 billion in 2024. This robust growth, boasting a compound annual growth rate (CAGR) of 10.4%, is attributed to factors such as delayed diagnosis, increased awareness, advances in laparoscopic surgery, hormonal therapies, and the influential role of patient advocacy and support groups.

Navigating the Future: Projected Expansion

Anticipating Progressive Trends

The journey doesn’t stop here; the endometriosis market is poised for continued expansion, forecasting a significant leap to $2.01 billion in 2028, boasting a CAGR of 9.3%. The upcoming growth surge is fueled by factors such as minimally invasive procedures, pharmaceutical innovations, genetic and epigenetic research, and the global expansion of women’s healthcare. Noteworthy trends in this period include a shift towards patient-centered care, precision medicine, virtual care, and telemedicine, with a growing emphasis on fertility preservation.

Elevated Ovarian Cancer Incidence Fuels Growth In The Endometriosis Market

Understanding the Catalyst

The rising incidence of ovarian cancer stands as a pivotal force driving the growth of the endometriosis market. Ovarian cancer, originating in the ovaries, poses a significant risk for individuals with endometriosis, particularly those with high estrogen concentrations. With projections indicating approximately 19,710 new cases of ovarian cancer in the US in 2023, the link between endometriosis and ovarian cancer is a crucial factor propelling market growth.

Ovarian Cancer Link: Endometriosis is associated with an increased risk of developing ovarian cancer, especially specific subtypes linked to high estrogen concentrations.
Alarming Statistics: In 2022, ovarian cancer caused 12,810 deaths, surging to 13,270 fatalities in 2023, as reported by the Ovarian Cancer Research Alliance.
Market Drivers: The increasing incidence of ovarian cancer significantly contributes to the expansion of the endometriosis market.
Key Players: Pfizer Inc., F. Hoffmann-La Roche AG, Merck And Co. Inc., among others, play pivotal roles in shaping the endometriosis market.

View More On The Endometriosis Market Report 2023 – https://www.thebusinessresearchcompany.com/report/endometriosis-global-market-report

Innovative Medications Reshaping Endometriosis Treatment Landscape

Pioneering Solutions

Major players in the endometriosis market are at the forefront of innovation, developing groundbreaking medications to address unmet needs in treatment. The approval of Myfembree, a once-daily pill combining relugolix, estradiol, and norethindrone acetate, exemplifies this commitment. Myfembree, approved in August 2022, offers a new dimension in managing moderate to severe pain associated with endometriosis, providing an alternative for those who cannot or prefer not to use hormone therapy.

Innovative Drug Approval :Myfembree, approved by the U.S. Food and Drug Administration, offers a comprehensive solution for premenopausal women.
Unique Formulation: Combining relugolix, estradiol, and norethindrone acetate in one pill provides proven relief with two indications.

Organon’s Strategic Acquisition Bolsters Women’s Health Portfolio With Endometriosis Focus

Strategic Growth Moves

In December 2021, Organon Group orchestrated a strategic move by acquiring Forendo Pharma Ltd. for $954 million. This acquisition, centered on endometriosis and polycystic ovarian syndrome (PCOS), is poised to expand Organon’s women’s health pipeline. Forendo Pharma, based in Finland, gains invaluable resources and expertise for advancing its endometriosis program into Phase II clinical studies.

Strategic Acquisition: Organon Group’s acquisition of Forendo Pharma strengthens its position in women’s health.
Pipeline Expansion: The acquisition broadens Organon’s women’s health pipeline with novel candidates targeting endometriosis and PCOS.

Segmentation Insights and Geographical Dominance

Decoding the Landscape

The endometriosis market, intricately segmented, encompasses various types, treatment options, drugs, and end-users. From superficial peritoneal lesions to hormonal therapies and pain management, the market caters to diverse needs. Notably, North America emerged as the largest region in the endometriosis market in 2023, showcasing the region’s dominance in this evolving landscape.

Segmentation Overview: The market is categorized by type, treatment type, drug, and end-user, offering tailored solutions for diverse patient needs.
Geographical Leadership: North America took the lead in 2023, solidifying its position as the largest region in the endometriosis market.

Request A Sample Of The Global Endometriosis Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=13035&type=smp

The Endometriosis Global Market Report 2023 provides an in-depth analysis on the endometriosis market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the endometriosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

View More Related Reports –

Female Fertility And Pregnancy Rapid Test Global Market Report 2023

Fertility Drugs Global Market Report 2023

Fertility Services Global Market Report 2023

Contact us at:
The Business Research Company:https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]